icad inc (ICAD) Key Developments
iCAD, Inc. Announces Commercial Availability of Cervical Applicator for Treatment of Gynecological Cancers
Jul 14 15
iCAD, Inc. announced the commercial availability of a new cervical applicator for the Xoft Axxent Electronic Brachytherapy System. The applicator and multi-platform controller will be showcased in the iCAD/Xoft booth (#1239) at the American Association of Physicists in Medicine (AAPM) annual meeting from July 12-16, 2015 in Anaheim, CA. Data from several studies involving use of surface HDR electronic brachytherapy is also being presented in multiple poster and oral presentations throughout the meeting. The cervical applicator, Xoft's first multi-channel applicator, is used to deliver a precise dose of radiation to larger target areas of the cervix while minimizing exposure to healthy tissue. The addition of the cervical applicator completes Xoft's gynecological product line, allowing radiation oncologists to treat all gynecological indications with the Xoft System.
iCAD Announces Launch of iReveal® Breast Density Analysis Solution as Latest Addition to PowerLook Advanced Mammography Platform
Jul 7 15
iCAD, Inc. announced the launch of the iReveal® breast density module as the latest addition to the Company's PowerLook Advanced Mammography Platform (AMP)®. The iReveal software is designed to deliver automated, rapid and reproducible assessments of breast density to help identify patients that may experience reduced sensitivity to digital mammography due to dense breast tissue. iReveal uses an advanced software program to assess breast density based on the range of categories established by the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS®), automating the same analytical approach used by many experienced radiologists. In many cases, patients with dense breast tissue may be recommended for additional screening exams including use of breast tomosynthesis.
iCAD, Inc. Withdraws 2015 Financial Guidance Due to General Reimbursement Uncertainty
May 27 15
iCAD, Inc. announced that it is withdrawing its full year 2015 financial guidance due to general uncertainty related to reimbursement for non-melanoma skin cancer in the United States. The company's guidance was based on the assumption that there would be no changes to the reimbursement environment for fiscal 2015. The company is proactively working to gain clarity on the issue and will provide an update on reimbursement when appropriate.
iCAD, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 04:00 PM
May 7 15
iCAD, Inc. Presents at 5th LD Micro Invitational Conference, Jun-02-2015 04:00 PM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States.
iCAD Launches Digital Customer Training Platform to Support Professional Education in Use Of Xoft System for Treatment of Non-Melanoma Skin Cancer, Early-Stage Breast Cancer and Gynecological Cancers
May 5 15
iCAD, Inc. announced the launch of an enhanced eBx Institute including a new online learning and support platform for Xoft Electronic Brachytherapy (eBx) System users. eBx Institute will offer healthcare providers access to training modules and educational resources to support the treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers using the Xoft System. The web-based solution provides an array of on-demand, self-paced learning programs, including instructional courses and reference materials. eBx Institute will enable customers to: Self-enroll in training - Search for online course offerings - Manage course enrollments - View/print transcripts and training certificates upon course completion - Review supplemental training materials - Watch instructional procedure videos and online simulations. Xoft System users may consult the available information for a variety of different purposes including pre-requisite training, continuing education and post-ILT (instructor-led training) reference. The site also provides information to customers and addresses questions.